BACKGROUND: Preclinical and clinical research suggests that the oxytocin system is implicated in the development and maintenance of stress and anxiety-related psychiatric conditions, such as posttraumatic stress disorder (PTSD). Recent research also suggests that intranasal oxytocin holds promise as a treatment for PTSD. However, little is known about the relationship between levels of peripheral oxytocin and PTSD symptom severity, PTSD treatment response, and repeated intranasal oxytocin administration. METHODS: In the current study, we examined associations between PTSD symptom severity and peripheral oxytocin levels measured in plasma before and after a course of prolonged exposure (PE) for PTSD (n = 13); participants were randomized to adjunctive intranasal oxytocin (n = 6) or placebo (n = 7). RESULTS: Baseline peripheral oxytocin levels were not associated with baseline PTSD symptom severity. Change in peripheral oxytocin levels did not differ by treatment condition and did not correspond to change in PTSD symptoms. CONCLUSIONS: This proof-of-concept study illustrates the acceptability and feasibility of measuring peripheral oxytocin among individuals engaged in psychotherapy for PTSD and informs the utilization of these procedures in future adequately powered studies.
BACKGROUND: Preclinical and clinical research suggests that the oxytocin system is implicated in the development and maintenance of stress and anxiety-related psychiatric conditions, such as posttraumatic stress disorder (PTSD). Recent research also suggests that intranasal oxytocin holds promise as a treatment for PTSD. However, little is known about the relationship between levels of peripheral oxytocin and PTSD symptom severity, PTSD treatment response, and repeated intranasal oxytocin administration. METHODS: In the current study, we examined associations between PTSD symptom severity and peripheral oxytocin levels measured in plasma before and after a course of prolonged exposure (PE) for PTSD (n = 13); participants were randomized to adjunctive intranasal oxytocin (n = 6) or placebo (n = 7). RESULTS: Baseline peripheral oxytocin levels were not associated with baseline PTSD symptom severity. Change in peripheral oxytocin levels did not differ by treatment condition and did not correspond to change in PTSD symptoms. CONCLUSIONS: This proof-of-concept study illustrates the acceptability and feasibility of measuring peripheral oxytocin among individuals engaged in psychotherapy for PTSD and informs the utilization of these procedures in future adequately powered studies.
Authors: Angela Szeto; Philip M McCabe; Daniel A Nation; Benjamin A Tabak; Maria A Rossetti; Michael E McCullough; Neil Schneiderman; Armando J Mendez Journal: Psychosom Med Date: 2011-06-02 Impact factor: 4.312
Authors: David L Lipschitz; Renee Kuhn; Anita Y Kinney; Karen Grewen; Gary W Donaldson; Yoshio Nakamura Journal: Integr Cancer Ther Date: 2015-04-14 Impact factor: 3.279
Authors: J L Frijling; M van Zuiden; L Nawijn; S B J Koch; I D Neumann; D J Veltman; M Olff Journal: J Neuroendocrinol Date: 2015-10 Impact factor: 3.627
Authors: Mikolaj Milewski; Adrian Goodey; Dinah Lee; Eric Rimmer; Robert Saklatvala; Shuzo Koyama; Mic Iwashima; Shunji Haruta Journal: Pharm Res Date: 2016-05-18 Impact factor: 4.200
Authors: David P Bernstein; Judith A Stein; Michael D Newcomb; Edward Walker; David Pogge; Taruna Ahluvalia; John Stokes; Leonard Handelsman; Martha Medrano; David Desmond; William Zule Journal: Child Abuse Negl Date: 2003-02
Authors: D S Quintana; L T Westlye; S Hope; T Nærland; T Elvsåshagen; E Dørum; Ø Rustan; M Valstad; L Rezvaya; H Lishaugen; E Stensønes; S Yaqub; K T Smerud; R A Mahmoud; P G Djupesland; O A Andreassen Journal: Transl Psychiatry Date: 2017-05-23 Impact factor: 6.222